Reynolds Mark A, Prudencio Almudena, Aichelmann-Reidy Mary E, Woodward Kevin, Uhrich Kathryn E
Department of Periodontics, University of Maryland Dental School, Baltimore, MD 21201, USA.
Curr Drug Deliv. 2007 Jul;4(3):233-9. doi: 10.2174/156720107781023866.
Bioresorbable polymers offer the potential to deliver biologically active agents that selectively modulate wound healing in bone and periodontal regeneration. This preliminary study characterizes early wound healing in calvarial defects grafted with demineralized bone matrix (DBM) overlaid with membranes made from a novel class of non-steroidal anti-inflammatory drug (NSAID)-derived poly(anhydride-esters). These polymers chemically incorporate either salicylic acid (SA) or 5-(2',4'-difluorophenyl)salicylic acid (diflunisal) into the polymeric backbone and release the NSAIDs upon hydrolysis. Inflammatory cell infiltrate in response to the novel NSAID-derived polymers was compared to defects grafted with DBM alone at 10 days and to defects grafted with DBM and overlaid with poly(lactic acid) (PLA; Atrisorb) at 21 days in 8 Wistar rats (350-450 g). Histological analysis of the calvarial sites at 10 days revealed that the NSAID-derived polymers were associated with moderate levels of inflammation similar to defects grafted without polymer (2.3 +/- 0.96 versus 2.0 +/- 0.82, respectively), consistent with the therapeutic activity of salicylic acid and diflunisal. Defects grafted with DBM and overlaid with NSAID-derived polymers at 21 days exhibited mild inflammation; whereas, defects treated with PLA were consistently associated with moderate to severe inflammatory cell infiltrate (1.8 +/- 0.50 versus 2.7 +/- 0.58, respectively). Histopathological findings, such as foreign body giant cells or fibrous encapsulation, were not observed in any defects with NSAID-derived polymers. Cellular features consistent with bone formation were found in all grafted defects. This novel class of non-steroidal anti-inflammatory drug-derived poly(anhydride-esters) were well tolerated and elicited no demonstrable increase in inflammation, as shown with PLA, during osseous wound healing in a regenerative application.
生物可吸收聚合物为递送生物活性剂提供了潜力,这些生物活性剂可选择性地调节骨愈合和牙周组织再生过程中的伤口愈合。这项初步研究对颅骨缺损早期伤口愈合情况进行了表征,这些缺损用脱矿骨基质(DBM)移植,并覆盖由一类新型非甾体抗炎药(NSAID)衍生的聚(酸酐 - 酯)制成的膜。这些聚合物将水杨酸(SA)或5 - (2',4'-二氟苯基)水杨酸(双氯芬酸)化学结合到聚合物主链中,并在水解时释放NSAIDs。在8只Wistar大鼠(350 - 450克)中,将对新型NSAID衍生聚合物产生反应的炎性细胞浸润情况与仅移植DBM的缺损在10天时的情况进行比较,并与在21天时移植DBM并覆盖聚乳酸(PLA;Atrisorb)的缺损情况进行比较。对10天时颅骨部位的组织学分析表明,NSAID衍生聚合物与中等程度的炎症相关,类似于未移植聚合物的缺损(分别为2.3±0.96和2.0±0.82),这与水杨酸和双氯芬酸的治疗活性一致。在21天时移植DBM并覆盖NSAID衍生聚合物的缺损表现出轻度炎症;而用PLA治疗的缺损始终与中度至重度炎性细胞浸润相关(分别为1.8±0.50和2.7±0.58)。在任何使用NSAID衍生聚合物的缺损中均未观察到组织病理学发现,如异物巨细胞或纤维包裹。在所有移植的缺损中均发现了与骨形成一致的细胞特征。在再生应用的骨伤口愈合过程中,这类新型非甾体抗炎药衍生的聚(酸酐 - 酯)具有良好的耐受性,并且没有像PLA那样引起炎症的明显增加。